PSPaula Schuster-Winkelmann

Paula Schuster-Winkelmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paula Schuster-Winkelmann has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Roswitha Gropp

    Department of General, Visceral, and Transplantation Surgery, LMU University Hospital, LMU Munich, Munich, Germany

    4 shared publications
  • Matthias Siebeck

    Affiliations CIH LMU, Center for International Health, LMU University Hospital, LMU Munich, Munich, Germany, Institute of Medical Education, LMU University Hospital, LMU Munich, Munich, Germany

    3 shared publications
  • Attila Aszodi

    Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Centre Munich (MUM), Ludwig-Maximilians-University (LMU), Munich, Germany

    2 shared publications
  • Florian Beigel

    Department of Medicine II Hospital of the LMU, Munich München Germany

    2 shared publications
  • Leandra Koletzko

    Department of Medicine II Hospital of the LMU, Munich München Germany

    2 shared publications
  • Marietta Seuß

    Department of General, Visceral and Transplantation Surgery Hospital of the LMU Munich Germany

    2 shared publications

Latest Publications

  • Open Access

    Validation of a model of rheumatoid arthritis using mice reconstituted with patient peripheral blood mononuclear cells

    by Paula Schuster-Winkelmann, Veronika Weß, Marietta Schindler, Morten Ø. Jensen, David E. Shaw, Paolo Alberton, Hendrik Schulze-Koops, Silvia Schoenthaler, Andreas Weinhaeusel, Matthias Siebeck, et al.

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint destruction. Replicating human manifestations of RA in animal models remains challenging, however, owing to heterogeneity of the disease. In this study, a humanized mouse model for RA was developed and validated using NOD-scid IL2Rγnull (NSG) mice engrafted with peripheral blood mononuclear cells (PBMCs) from patients with RA (NSG-RA). RA symptoms were induced using lipopolysaccharide and a cocktail of antibodies against type II collagen. Pathological manifestations were assessed through clinical scoring of hind paw swelling, histological analysis, and evaluation of RA-specific markers in plasma and joints using Luminex, RT-PCR and RNA sequencing. NSG-RA mice exhibited increased levels of RA-specific markers, an influx of inflammatory cells into the synovium, bone erosion and elevated levels of human autoantibodies. Enriched RNA-sequencing pathway analysis revealed activation of the RA disease pathway, along with the TNF and IL-17 signalling pathways. Treatment with prednisolone or infliximab ameliorated disease symptoms and decreased levels of inflammatory markers. These findings indicate that the NSG-RA model offers a translational tool for studying RA pathogenesis and testing novel therapeutic approaches.


  • Open Access

    NOD/Scid IL2Rγnull Mice Reconstituted with PBMCs from Patients with Atopic Dermatitis or Psoriasis Vulgaris Reflect the Respective Phenotype

    by Marietta Schindler, Paula Schuster-Winkelmann, Veronika Weß, Sophia Czell, Franziska Rueff, Andreas Wollenberg, Matthias Siebeck, Roswitha Gropp


  • Open Access

    Humanized NSG Mouse Models as a Preclinical Tool for Translational Research in Inflammatory Bowel Diseases

    by Veronika Weß, Paula Schuster-Winkelmann, Yasemin Hazal Karatekin, Simge Malik, Florian Beigel, Florian Kühn, Roswitha Gropp

    The development of animal models reflecting the pathologies of ulcerative colitis (UC) and Crohn’s disease (CD) remains a major challenge. The NOD/SCID/IL2rγnull (NSG) mouse strain, which is immune-compromised, tolerates the engraftment of human peripheral blood mononuclear cells (PBMC) derived from patients with UC (NSG-UC) or CD (NSG-CD). This offers the opportunity to examine the impact of individual immunological background on the development of pathophysiological manifestations. When challenged with ethanol, NSG-UC mice exhibited a strong pro-inflammatory response, including the development of edemas, influx of human T cells, B cells and monocytes into the mucosa and submucosa, and elevated expression of the inflammatory markers CRP and CCL-7. Fibrotic alterations were characterized by an influx of fibroblasts and a thickening of the muscularis mucosae. In contrast, the development of pathological manifestations in NSG-CD mice developed without challenge and was signified by extensive collagen deposition between the muscularis propria and muscularis mucosae, as observed in the areas of strictures in CD patients. Vimentin-expressing fibroblasts supplanting colonic crypts and elevated expression of HGF and TGFß corroborated the remodeling phenotype. In summary, the NSG-UC and NSG-CD models partially reflect these human diseases and are powerful tools to examine the mechanism underlying the inflammatory processes in UC and CD.


  • Open Access

    NOD/scid IL‐2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn's disease reflect the human pathological phenotype

    by Anna‐Lena Unterweger, Alena Rüscher, Marietta Seuß, Paula Winkelmann, Florian Beigel, Leandra Koletzko, Simone Breiteneicher, Matthias Siebeck, Roswitha Gropp, Attila Aszodi

    Introduction: Crohn's disease (CD) is characterized by pronounced intestinal fibrosis and severe mucosal damage and conventional animal models are limited to reflect these pathological manifestations. The aim of this study was to examine whether the combination of patient immune‐profiling and preclinical studies in a mouse model based on NOD/scid IL‐2Rγnull (NSG) reconstituted with peripheral blood mononuclear cells (PBMC) from CD patients has the capacity to harmonize ex vivo human and in vivo animal studies.Methods: Immunological profiles of CD (n = 24) and ulcerative colitis (UC) patients (n = 47) were established by flow cytometry of subgroups of immune cells and subjected to hierarchical cluster and estimation graphics analyses. Pathological phenotypes of NSG mice, which were reconstituted with PBMC from CD, UC, and non‐IBD donors (NSG‐CD, NSG‐UC, and NSG‐non‐IBD) were compared. Readouts were the clinical, colon, and histological scores; subtypes of immune cells from spleen and colon; and levels of inflammatory markers, such as c‐reactive protein (CRP), monocyte chemotactic protein (MCP)‐3, transforming growth factor‐beta (TGFß), and hepatocyte growth factor (HGF). Fibrocytes were identified by immunohistochemistry in colonic sections.Results: CD patients were significantly clustered in a group characterized by increased levels of TH1, TH2 cells, and decreased levels of CD14+ CD163+ monocytes (p = .003). In contrast to NSG‐UC mice, NSG‐CD mice exhibited an immune‐remodeling phenotype characterized by enhanced collagen deposition, elevated levels of CD14+ CD163+ monocytes, HGF, and TGFß. This phenotype was further corroborated by the presence of human fibrocytes as components of fibrotic areas.Conclusion: The NSG‐CD model partially reflects the human disease and allows for studying the development of fibrosis.


  • Open Access

    Suppressing Kv1.3 Ion Channel Activity with a Novel Small Molecule Inhibitor Ameliorates Inflammation in a Humanised Mouse Model of Ulcerative Colitis

    by Anna-Lena Unterweger, Morten Ø Jensen, Fabrizio Giordanetto, Vishwanath Jogini, Alena Rüschher, Marietta Seuß, Paula Winkelmann, Leandra Koletzko, David E Shaw, Matthias Siebeck, et al.

    The potassium channel Kv1.3 is a potentially attractive therapeutic target in T cell-mediated inflammatory diseases, as the activity of antigen-activated T cells is selectively impeded by Kv1.3 inhibition. In this study, we examined Kv1.3 as a potential therapeutic intervention point for ulcerative colitis [UC], and studied the efficacy of DES1, a small-molecule inhibitor of Kv1.3, in vitro and in vivo. Kv1.3 expression on T cells in peripheral blood mononuclear cells [PBMCs] isolated from donors with and without UC was examined by flow cytometry. In biopsies from UC patients, Kv1.3-expressing CD4+ T cells were detected by flow cytometry and immunohistochemistry. In vitro, we determined the ability of DES1 to inhibit anti-CD3-driven activation of T cells. In vivo, the efficacy of DES1 was determined in a humanised mouse model of UC and compared with infliximab and tofacitinib in head-to-head studies. Kv1.3 expression was elevated in PBMCs from UC patients and correlated with the prevalence of TH1 and TH2 T cells. Kv1.3 expression was also detected on T cells from biopsies of UC patients. In vitro, DES1 suppressed anti-CD3-driven activation of T cells in a concentration-dependent manner. In vivo, DES1 significantly ameliorated inflammation in the UC model and most effectively so when PBMCs from donors with higher levels of activated T cells were selected for reconstitution. The efficacy of DES1 was comparable to that of either infliximab or tofacitinib. Inhibition of Kv1.3 [by DES1, for instance] appears to be a potential therapeutic intervention strategy for UC patients.